USFE - ETF AI Analysis
Top Page
First Eagle US Equity ETF (USFE)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Leading Holdings
Several of the largest positions, such as Alphabet, Oneok, Bank of New York Mellon, Oracle, and Colgate-Palmolive, have shown strong gains this year, helping support the fund’s results.
Broad Sector Diversification
The ETF spreads its investments across many sectors, including health care, communication services, technology, financials, materials, energy, and others, which helps reduce the impact of weakness in any single industry.
Balanced Mix of Defensive and Growth Areas
Holdings in defensive sectors like health care and consumer defensive, alongside growth-oriented areas like technology and communication services, provide a blend of stability and growth potential.
Negative Factors
Recent Weak Overall Performance
The fund has delivered slightly negative results over the year to date and over the past three months, which may concern investors looking for stronger recent momentum.
Underperforming Key Holdings
Some sizable positions, including Meta Platforms, Becton Dickinson, and HCA Healthcare, have shown weak performance this year, which can drag on the ETF’s returns.
High U.S. Market Concentration
With almost all assets invested in U.S. companies, the fund offers little geographic diversification and is heavily exposed to the U.S. market’s ups and downs.
USFE vs. SPDR S&P 500 ETF (SPY)
AUM2.11M
RegionNorth America
Expense Ratio0.45%
Beta0.61
IssuerFirst Eagle
Inception DateJan 27, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume160
30 Day Avg. Volume744
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.39Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering56
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
USFE Summary
The First Eagle US Equity ETF (USFE) is an actively managed fund that invests in a wide range of U.S. companies, from small to large, with a focus on stocks the managers believe are priced below their true value. It doesn’t track a specific index, but aims for broad U.S. market exposure with a value tilt. The fund holds well-known companies like Alphabet (Google’s parent) and Meta Platforms (Facebook). Investors might consider USFE for diversified U.S. stock exposure with professional stock picking. However, its share price can go up and down with the stock market and value-style stocks may lag growth stocks at times.
How much will it cost me?This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 you invest. That’s higher than the cost of many index (passively managed) ETFs, mainly because this fund is actively managed, with managers researching and selecting individual stocks.
What would affect this ETF?USFE could benefit if the U.S. economy stays resilient, as its broad mix of sectors and value focus may help it find solid companies that are temporarily out of favor, especially in areas like health care, communication services, and technology where leaders such as Alphabet and Meta could gain from ongoing digital and medical trends. On the other hand, rising interest rates, tighter regulations on big tech or financial firms, or a downturn that hits value stocks or U.S. markets in general could weigh on the fund’s performance despite its diversification.
USFE Top 10 Holdings
USFE leans into a U.S.-only mix of value-tilted blue chips, with health care, tech, and financials quietly steering the ship. Alphabet is still a key engine for returns, with gains over the past few months despite a recent stumble, while Meta has been more of a backseat driver lately, losing steam after earlier strength. Oracle has turned into a surprise powerhouse, rising on cloud and AI enthusiasm. On the steadier side, Bank of New York Mellon and Elevance Health are providing a solid backbone, helping offset laggards like Becton Dickinson and HCA Healthcare in the health care sleeve.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Alphabet Class C | 4.81% | $99.95K | $4.49T | 109.10% | 82 Outperform | |
| Oneok | 4.68% | $97.16K | $56.04B | 7.99% | 82 Outperform | |
| Meta Platforms | 4.23% | $87.84K | $1.59T | -15.01% | 76 Outperform | |
| Oracle | 3.93% | $81.54K | $679.72B | 22.79% | 66 Neutral | |
| Bank of New York Mellon | 3.81% | $79.14K | $98.85B | 57.65% | 75 Outperform | |
| Elevance Health | 3.56% | $73.95K | $88.91B | 5.64% | 76 Outperform | |
| Becton Dickinson | 3.39% | $70.33K | $41.21B | -12.85% | 67 Neutral | |
| Philip Morris | 3.13% | $65.10K | $272.73B | -1.89% | 61 Neutral | |
| HCA Healthcare | 2.90% | $60.30K | $80.27B | -3.18% | 70 Neutral | |
| Salesforce | 2.49% | $51.66K | $154.59B | -32.37% | 80 Outperform |
USFE Technical Analysis
Negative
―
Price Trends
34.38
Positive
Market Momentum
0.10
Positive
48.44
Neutral
43.15
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For USFE, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 34.74, equal to the 50-day MA of 34.38, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 48.44 is Neutral, neither overbought nor oversold. The STOCH value of 43.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for USFE.
USFE Peer Comparison
Comparison Results
Performance Comparison
USFE
First Eagle US Equity ETF
34.61
-0.41
-1.17%
GMOV
GMO US Value ETF
―
―
―
SASS
M.D. Sass Concentrated Value ETF
―
―
―
VUSV
Vanguard Wellington U.S. Value Active ETF
―
―
―
GVLE
Goldman Sachs Value Opportunities ETF
―
―
―
CVAR
Cultivar ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents